Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
AI-biomarker voor respons op atezolizumab-bevacizumab bij HCC
jan 2024 | Maag-darm-leveroncologie